Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

被引：0
|
作者：
Cull, Gavin
Opat, Stephen
Trotman, Judith
Hilger, James
Zhang, Xiaoping
Feng, Shibao
Ro, Sunhee
Huang, Jane
Tam, Constantine S.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4057
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma
    Tam, Constantine S.
    Simpson, David
    Opat, Stephen
    Kim, Won Seog
    Wang, Michael
    Cull, Gavin
    Johnston, Patrick B.
    Munoz, Javier
    Lee, Won-Sik
    Marlton, Paula
    Gottlieb, David
    Wang, Lai
    Huang, Jane
    Hilger, James
    Xue, Ling
    Ro, Sunhee
    Trotman, Judith
    BLOOD, 2017, 130
  • [2] BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China
    Zhu, Jun
    Li, Jianyong
    Zhou, Jianfeng
    Song, Yuqin
    Qi, Junyuan
    Xu, Wei
    Li, Dengju
    Sun, Mingyuan
    Xue, Ling
    Yang, Liudi
    Zhang, Yinwei
    Wang, Lai
    Huang, Jane
    Feng, Shibao
    Qiu, Lugui
    BLOOD, 2017, 130
  • [3] The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial
    Tam, Constantine
    Grigg, Andrew P.
    Opat, Stephen
    Ku, Matthew
    Gilbertson, Michael
    Anderson, Mary Ann
    Seymour, John F.
    Ritchie, David S.
    Dicorleto, Carmen
    Dimovski, Belinda
    Hedrick, Eric
    Yang, Jianxin
    Wang, Lai
    Luo, Lusong
    Xue, Ling
    Roberts, Andrew W.
    BLOOD, 2015, 126 (23)
  • [4] An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies
    Tam, Constantine S.
    Cull, Gavin
    Opat, Stephen
    Gregory, Gareth P.
    Liu, Aichun
    Johnston, Anna M.
    Zhao, Weili
    Roncolato, Fernando
    Handunnetti, Sasanka M.
    Prince, H. Miles
    Yannakou, Costas K.
    Li, Wenyu
    Shih, Ted
    Zhang, Xiaoping
    Wu, Ken
    Liu, Yuan
    Huang, Jane
    Trotman, Judith
    BLOOD, 2019, 134
  • [5] Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma
    Tam, Constantine S.
    Wang, Michael
    Simpson, David
    Opat, Stephen
    Cull, Gavin
    Munoz, Javier
    Phillips, Tycel J.
    Kim, Won-Seog
    Hilger, James
    Huang, Jane
    Novotny, William
    Trotman, Judith
    BLOOD, 2018, 132
  • [6] A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
    Friedlander, Michael
    Meniawy, Tarek
    Markman, Ben
    Mileshkin, Linda R.
    Harnett, Paul R.
    Millward, Michael
    Lundy, Joanne
    Freimund, Alison E.
    Norris, Christie
    Mu, Song
    Wu, John
    Paton, Virginia E.
    Wang, Lai
    Gao, Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
    Friedlander, Michael
    Meniawy, Tarek
    Markman, Ben
    Mileshkin, Linda R.
    Harnett, Paul
    Millward, Michael
    Lundy, Joanne
    Freimund, Alison E.
    Norris, Christie
    Wu, John
    Paton, Virginia
    Wang, Lai
    Gao, Bo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [8] Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial
    Song, Yuqin
    Zhou, Keshu
    Zou, Dehui
    Zhou, Jianfeng
    Hu, Jianda
    Yang, Haiyan
    Zhang, Huilai
    Ji, Jie
    Xu, Wei
    Jin, Jie
    Lv, Fangfang
    Feng, Ru
    Gao, Sujun
    Zhou, Daobin
    Guo, Haiyi
    Wang, Aihua
    Hilger, James
    Huang, Jane
    Novotny, William
    Osman, Muhtar
    Zhu, Jun
    BLOOD, 2018, 132
  • [9] A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data
    Soumerai, Jacob D.
    Opat, Stephen
    Cheah, Chan Y.
    Lasica, Masa
    Verner, Emma
    Browett, Peter J.
    Chan, Henry
    Barca, Eva Gonzalez
    Hilger, James
    Fang, Yiqian
    Simpson, David
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S267 - S268
  • [10] Twice Daily Dosing With the Highly Specific BTK Inhibitor, BGB-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated With Durable Responses in Patients (pts) With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 11 - 12
12345